Drug intelligence / Profile preview

RV299

Development stage: Phase 1
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

RV299 is an investigational small molecule antiviral drug developed for the treatment of respiratory syncytial virus (RSV) infection. It acts as an inhibitor of **nuclear proteins**, targeting viral replication processes. The drug has been evaluated in phase 1 and phase 1b clinical trials to assess its safety, pharmacokinetics, tolerability, and antiviral activity in healthy adults using a viral challenge model with RSV-A Memphis 37b. The studies have shown that orally administered RV299 is safe and well tolerated at tested doses[1][3][4][5][7]. Initial development was by ReViral Ltd., with Pfizer also listed as a sponsor/collaborator in later studies[1].

Other names: RV-299RV299RV 299

Targets

RSV N (Respiratory syncytial virus nucleoprotein)

Beyond the preview

Go deeper on RV299.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RV299.

Explore the full profile